The U.S. Food and Drug Administration has approved the use of certolizumab pegol (which will be marketed under the trade name Cimzia) for the treatment of moderate to severe rheumatoid arthritis (RA). Certolizumab pegol is a novel TNF inhibitor comprised of an antigen-binding domain of a humanized TNF antibody coupled to polyethylene glycol (PEG) to [...]
Approval for golimumab (which will by marketed under the trade name Simponi) was granted this week by the U.S. Food and Drug Administration. The drug received approval for the treatment of moderate to severe RA (in conjunction with methotrexate), active psoriatic arthritis (as monotherapy or with methotrexate), and active ankylosing spondylitis at a dose of [...]
Cases of new onset psoriasis in patients receiving TNF inhibitors for the treatment of rheumatoid arthritis (RA) have been reported; however, case reports do not permit the calculation of drug-associated incidence rates. Here, Harrison et al (Ann Rheum Dis 2009; 68: 209) compare incident psoriasis in TNF inhibitor treated vs. untreated patients enrolled in the [...]
RA patients who use methotrexate have been shown to have lower cardiovascular mortality compared to non-users; however, the mechanism underlying this protection is unclear. Here, Reiss et al (Arthritis Rheum 2008; 58(12): 3675) explore the atheroprotective effects of methotrexate in an experimental model of atherogenesis. Methods THP-1 monocytes/macrophages and human donor peripheral blood mononuclear cells [...]
The efficacy of rituximab, a monoclonal antibody directed against CD20 positive B cells, has been demonstrated for the treatment of rheumatoid arthritis (RA) in a number of key studies. However, not all patients respond to therapy. Whether patients with initial non-response may benefit from follow-up treatments (i.e. initial treatment resistance) has not been investigated.